Free Trial

For a free trial of HEPATIQ at your institution, please submit:

investors

PROBLEM: Infections, alcohol and fat can cause fibrosis in the liver. Fibrosis leads to non-functional scar tissue. Other products estimate the extent of fibrosis, which is a partial view since the liver compensates by generating new functioning lobules and increasing blood flow to improve function. It is the liver functional reserve that determines disease outcomes. Estimating fibrosis alone is not enough. SOLUTION: Patient is injected with a standard low dose radioisotope and imaged with SPECT. HEPATIQ analyzes the images to provide 6 indices of liver disease: PHM® (perfused hepatic mass), fLV® (liver volume), fSV® (spleen volume), HAI® (activity index), eFS® (fibrosis score), and eEV® (esophageal varices). It provides a physiologic stage: H0 (normal liver function) to H5 (transplant candidate). HEPATIQ is cleared by the FDA and generating revenues. For more information, please click the link below.

EMPLOYMENT

Reasons to join Hepatiq, Inc:
  • HEPATIQ is the only FDA cleared quantitative liver function product on the market
  • Other tests estimate liver fibrosis; function outperforms fibrosis in predicting outcomes
  • 4 issued US patents and 5 foreign patents; 9 registered trademarks
  • Liver diagnostics market is $8 billion/year worldwide, growing 12% per year
  • Customer gets get reimbursement from patients’ insurance and pays us.
  • Pure software product; zero manufacturing cost resulting in strong margins.
Open positions are listed below.

LOCATION

Hepatiq, Inc. 1200 Main Street, Suite B Irvine, CA 92614, USA. www.hepatiq.com sales@hepatiq.com